These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15035755)

  • 1. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
    McCoy C; Matthews SJ
    Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
    Rice TW; Bernard GR
    Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of septic shock and use of drotrecogin alfa (activated) in children.
    Marraro GA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):769-72. PubMed ID: 19735218
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
    N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa (activated) in severe falciparum malaria.
    Kendrick BJ; Gray AG; Pickworth A; Watters MP
    Anaesthesia; 2006 Sep; 61(9):899-902. PubMed ID: 16922759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
    Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
    Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated recombinant protein C in septic shock early after liver transplantation: a case report.
    Feltracco P; Bortolato A; Rizzi S; Barbieri S; Furnari M; Serra E; Milevoj M; Ori C
    Transplant Proc; 2008; 40(6):2070-2. PubMed ID: 18675133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis.
    Castelli EE; Culley CM; Fink MP
    Pharmacotherapy; 2005 Aug; 25(8):1147-50. PubMed ID: 16207107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
    McCoy C
    Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
    Bernard GR
    Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient.
    Huston JM; Eachempati SR; Rodney JR; Cayci C; Fusco D; Mathew M; Shou J; Goldstein MJ; Kapur S; Barie PS
    Transpl Infect Dis; 2009 Jun; 11(3):277-80. PubMed ID: 19392733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated).
    Lyseng-Williamson KA; Perry CM
    Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
    Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
    Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.